Phase 2 N=25 A Study of E6011 in Participants With Active Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Clinical Response (CR) 100 (CR100) at Week 12 — 33.3; 23.1 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=216 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Cancer
Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT
Phase 2 N=288 L9LS MAb in Malian Adults
Plasmodium Falciparum Infection · Malaria
Primary: Number of Participants With Local Adverse Events (AEs) — 7; 1; 0; 0 Participants
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 2 N=24 Therapeutic Effects of Topical Herbal Medicine -Rhubarb Ointment on Rosacea
Rosacea · Chinese Herbal Medicine
Primary: Reduction of Flushing, Erythema, Telangiectasia, Papules, and Pustules — 1; 1.92 score on a scale
Phase 2 N=11 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · CAH - Congenital Adrenal Hyperplasia · CAH - 21-Hydroxylase Deficiency
Primary: The Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) in Subjects With CAH — 9; 2 Participants
Phase 2 N=9 Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer · KRAS Mutation-Related Tumors
Primary: Objective Response Rate — 9 Participants
Phase 2 N=80 Speech Entrainment for Aphasia Recovery
Aphasia · Aphasia Non Fluent · Stroke
Primary: Average Verbs Per Minute (VPM) Change From Baseline — 0.3; 0.62; -0.26; 0.52 verbs per minute
Phase 2 N=82 Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
Prostate Carcinoma
Primary: Change in Weekly Patient-reported Hot Flash Scores — -9.94; -13.95; -4.85 units on a scale — p=0.0019
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 2 N=103 Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Change From Baseline in Aberrant Behavior Checklist (ABC) Subscale Total Scores — -6.35; -5.41; -6.67; -8.05 score on a scale — p==0.085
Phase 2 N=24 Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)
Hepatocellular Carcinoma
Primary: Rate of Adverse Events (AE) ≥ Grade 3 (CTCAE 5.0) Excluding Palmar-plantar Erythrodysesthesia — 16 Participants
Phase 2 N=59 A Novel Wearable Device to Improve Sleep Quality
Insomnia
Primary: Insomnia Symptoms — -7.34; -7.58 score on a scale — p=.88
Phase 2 N=21 Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: HS Physician Local Improvement Assessment - PAIN — 7; 7; 2 Participants
Phase 2 N=53 A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Primary: BCVA Response Defined as an Increased in 10 Letters at 1 Year Post-implant — 3; 3; 1; 9 eyes